The firms noted that QuantuMDx’s Capture-XT technology will enable downstream drug-susceptibility analysis, PCR, NGS, and, with this collaboration, nanopore detection.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
The funding will be used to further develop a 20-minute tuberculosis detection assay and drug susceptibility test using the firm's handheld Q-POC microfluidic PCR system.
At the Lancet, more than two dozen public health researchers condemn the conspiracy theories that have emerged surrounding the source of the COVID-19 outbreak.
In Nucleic Acids Research this week: pipeline for genotyping Alu retrotransposon mobile element insertions, previously undocumented non-coding RNAs, and more.
